Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheumatic Diseases. A wonderful resource in talking to our patients about vaccine necessity! @CleClinicMD https://t.co/EA5jVYweHm

#ACR21 Late breaking #ACRambassador Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled EMR Data Repository https://t.co/oyovR27Upm

• Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patie…

Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study: 🔰Vaccine being “rushed” or “experimental” 🔰Safety of vaccine in the patients’ rheumatologic diagnoses 🔰Side effects 🔰Concern for Allergic reaction Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56

Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting. https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke

• https://bit.ly/3qngYfx

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus? https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T

• https://bit.ly/3mXArBA

GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O

🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNow https://t.co/xzOaFIu06e @RheumNow https://t.co/tmr4USETJ3

• https://bit.ly/301hRiN

#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest https://t.co/F15j93OFE4 https://t.co/tXoisoYthx

• Additional Heterologous versus Homologous Booster Vaccination in Immunosuppress…

CH COVID 19 Poster Review Abst 0196 Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm - Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome #ACR21 @RheumNow https://t.co/hX7bBtrIzT

Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response. Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow https://t.co/lIDPzybmT7 https://t.co/jEJ3N6cdjK

• Additional Heterologous versus Homologous Booster Vaccination in Immunosuppress…

Complications of Covid19 in Lupus: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #1933 presented at the #ACR21 annual meeting. https://t.co/jKFJwCBeCo https://t.co/ncleyYZWLn

• https://bit.ly/3qj7KBa